|
Leukocytes with bound platelets as a predictive biomarker for immune-related adverse events (irAEs) in advanced non-small cell lung cancer (NSCLC) patients (pts) receiving anti-PD-(L)1 agents. |
|
|
Research Funding - Bristol-Myers Squibb |
|
|
Research Funding - Bristol-Myers Squibb |
|
|
Consulting or Advisory Role - Boehringer Ingelheim; Novartis; Roche |
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Merck; Pfizer; Roche |
Research Funding - Bristol-Myers Squibb |
|
|
Research Funding - Bristol-Myers Squibb |
|
|
Honoraria - Kiowa Kirin; Roche |
Consulting or Advisory Role - Roche |
Speakers' Bureau - Acraf; Kiowa Kirin; Roche |
Research Funding - Bristol-Myers Squibb |
Expert Testimony - Kiowa Kirin; Roche |
Travel, Accommodations, Expenses - Boehringer Ingelheim; MSD; Pfizer; Roche |
|
|
Research Funding - Bristol-Myers Squibb |
|
|
Research Funding - Bristol-Myers Squibb |
|
|
Research Funding - Bristol-Myers Squibb |
|
|
Research Funding - Bristol-Myers Squibb |
Travel, Accommodations, Expenses - Astellas Amgen BioPharama; Merck |
|
|
|
Consulting or Advisory Role - Lilly; Novartis; Pfizer |
Speakers' Bureau - Genomic Health International; Novartis; Pfizer; Roche |
Travel, Accommodations, Expenses - Pfizer; Roche |
|
|
Consulting or Advisory Role - Abbvie; Novartis; Sanofi |
Research Funding - Bristol-Myers Squibb; Novartis |
|
|
No Relationships to Disclose |